- Report
- May 2024
- 132 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 131 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2024
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- November 2024
- 216 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Clinical Trials
- April 2024
- 220 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- December 2024
- 171 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- December 2024
- 30 Pages
Global
From €2614EUR$2,750USD£2,196GBP
- Clinical Trials
- December 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Clinical Trials
- December 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- October 2024
- 170 Pages +
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- October 2024
- 203 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- September 2024
- 343 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- August 2024
- 121 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- October 2024
- 250 Pages
Global
From €4705EUR$4,949USD£3,952GBP

The Bronchodilator market is composed of inhalers and nebulisers, both of which are used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Inhalers are handheld devices that deliver medication directly to the lungs in the form of a mist or spray. Nebulisers are larger machines that convert liquid medication into a fine mist that can be inhaled. Both inhalers and nebulisers are used to deliver bronchodilators, which are medications that relax the muscles in the airways and make it easier to breathe.
Inhalers are the most commonly used form of bronchodilator delivery, as they are more convenient and cost-effective than nebulisers. Inhalers come in a variety of forms, including metered dose inhalers (MDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs). Nebulisers are typically used for more severe cases of respiratory conditions, as they can deliver a higher dose of medication than inhalers.
Some of the companies in the Bronchodilator market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Merck. Show Less Read more